Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature

Malik Ghannam1*, Shaden Mansour2, Aya Nabulsi2 and Qusay Abdoh1

Abstract

Background: Hypersensitivity is a rare adverse drug reaction (ADR) associated with anti-epileptic medications. Phenyltoin is one of the commonly used drugs for treatment of epilepsy that encounters a hypersensitivity reaction. This reaction can be ranged from mild cutaneous rash to anticonvulsant hypersensitivity syndrome (AHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) that includes fever, rash, eosinophilia and involvement of multiple internal organs.

Case presentation: A 15 year old middle eastern female patient from Gaza strip with free past medical and allergic history. She presented to An-Najah National University Hospital (NNUH) in Nablus with intermittent high grade fever, jaundice, rash and skin peeling. On examination, she had axillary and inguinal lymphadenopathy, moderate splenomegaly and diffuse maculopapular rash. The patient was on phenytoin which started 1 month prior to her presentation as a seizure prophylaxis due to previous head injury. Eventually, the patient was diagnosed with AHS/DRESS.

Conclusions: AHS is a diagnosis of exclusion and it is significantly underreported that requires a high index of suspicion. We liked to share this case and shed the light in more details on AHS/DRESS. Our goal was to help making AHS more reported in the literature in adolescent patients, as well as to make physicians more alert of this condition’s seriousness when they prescribe antiepileptic medications in particular. In this report, we included the first case of AHS which was reported in an adolescent patient in Palestine. Moreover, we reviewed the available literature for a better understanding of the pathophysiology and management of AHS. We still believe that the full understanding of the pathogenesis of AHS is lacking, and also we are lacking a clinical tool or scoring system to determine the severity of AHS/DRESS.

Keywords: Phenyltoin, Hypersensitivity, Adolescent patient, Rare condition, DRESS, Case report, Literature review
1000–10,000 exposures [8]. Since most of the cases are underreported and unrecognized, its true incidence still unknown [6]. Previous evidence suggested that there is no gender variation in the development of AHS [2]. Because many recent studies conclude that women especially fertile women are more prone to this drug reaction, hormonal phenomenon might be included in the pathogenesis of AHS [9]. The majority of the reported cases has been in african american patients [7]. It is worth mentioning that AHS has an autosomal dominant inheritance pattern; with increased susceptibility between siblings of affected patients [10]. A high rate of cross-reactivity among aromatic anti epileptic drugs (AEDS) is of concern and may be as high as 80% [10]. AHS is previously known as drug reaction with eosinophilia and systemic syndrome (DRESS) [9].

Although the exact mechanism of AHS remains not well understood, genetic factors may predispose to its occurrence. The human leukocyte antigen HLA-A*3101 was found to be associated with the carbamazepine cutaneous reaction in patients with the European origin [4]. Human herpesvirus 6 (HHV6) and/or human herpesvirus 7 (HHV7), CMV and EBV are all associated with AHS [3]. Reactivation of HHV6 was particularly linked to AHS/DRESS, which may be related to reduced CD19B cells [11] and enhanced T helper cell type 2 activity that occurs in HHV6 reactivation [12]. While, some studies conclude that anti-epileptic medications may resemble viral infection by enhancing the CD4 and CD8 T Cells activity resulting in increase of IL5, which play a major role in the maturation of the eosinophils [13]. AHS is generally thought to be a type IV T cell mediated delayed hypersensitivity reaction [6]. However, it is postulated that anti-epileptic medications containing aromatic ring are metabolized to arene oxide metabolites by hepatic cytochrome P450. Defective detoxification and elimination have been identified in patients with AHS. The accumulation of these metabolites stimulates cell necrosis and immunological response by binding to cellular macromolecules which explains AHS symptoms [10].

In this article, we report an interesting case of AHS 1 month after phenytoin administration with a significant hepatic injury in an adolescent patient in Palestine.

**Case presentation**

A 15 year old middle eastern female patient from Gaza strip with free past medical and allergic history who was admitted at our internal medicine department on July 20, 2016. At time of admission, she had intermittent high grade fever and sore throat for 1 week duration. Additionally, a non-itchy skin eruption was noticed for 2 weeks duration. As well as she started to have yellowish eye discoloration 5 days after the onset of fever. The patient was taking phenytoin 200 mg QD PO as a seizure prophylaxis since she had significant head trauma 4 weeks prior to her presentation.

She denied any history of red eye, digital swelling, seizures, photophobia or any weight changes. Family history was unremarkable. She was sexually inactive and started to have irregular menstruation 1 year before the time of admission. In addition to phenytoin, her only medication at the time of admission was acetaminophen 500 mg twice daily.

On physical examination, she was alert, oriented and conscious. Her hemodynamics were stable. Temperature 39.9 C and her tonsils were erythematous. Generally, she looked deeply jaundiced as well as fatigued. Systemic examination was normal except maculopapular rash on her limbs, abdomen, chest and back (Figs. 1, 2) besides peeling on both palms (Figs. 3, 4). On abdominal examination, the spleen was palpable 2 cm below costal margin and her liver was palpable and tender as well. She also had left axillary and inguinal lymphadenopathy around 1 × 1 cm in diameter each.

Abdominal ultrasound was done and showed moderate hepatosplenomegaly, in addition to that, there was enlarged retroperitoneal, portahepatis and mesenteric lymph nodes. She also underwent brain MRI which did not show any intracranial pathology. Liver Doppler and cardiac echocardiography were both normal. Chest x-ray and EKG were normal as well. Laboratory work up was summarized in Table 1.
Beside AHS, autoimmune hepatitis and infectious mononucleosis were suspected at that time. Phenytoin was stopped as well as acetaminophen due to elevated liver enzymes. The patient was given IV hydrocortisone. Over 10 days of admission, her condition significantly improved then she was sent home. The patient was seen 1 month after her discharge, at that time, the fever was gone, the rash was resolved and her liver enzymes were normalized.

**Discussion**

AHS is mainly characterized by high intermittent fever, skin rash, eosinophilia and internal organ abnormalities [14]. Fever is the most common manifestation occurring in approximately 90–100% of exposures. Commonly, fever and malaise are the first manifestations [4]. Skin rash is seen in 90% of the AHS cases, which is mainly a maculopapular eruption with subsequent desquamation during resolution [1]. Moreover, the rash can be ranged from morbilliform eruption to more severe forms like Steven Johnson syndrome or toxic epidermal necrosis [15]. The incidence of these two syndromes is about 9% in AHS patients [16]. The cutaneous reaction to anticonvulsants medications is typically known as pseudolymphoma.
due to the similarities in histology and clinical presentation with malignant lymphoma [17]. Skin biopsy usually reveals T lymphocyte infiltration and tissue eosinophilia [18, 19]. Noticeably, carbamazepine is associated with a higher incidence of skin reaction compared to phenytoin and lamotrigine. Whereas valproic acid and topiramate are rarely associated with skin manifestation [9]. Table 2 summarizes the adverse reactions associated with some anticonvulsant medications.

Systemic involvement is the major cause of mortality and morbidity in AHS. Liver is the most frequently affected internal organ occurring in 50–60% of cases [14]. Hepatic involvement could be just an elevation of the liver enzymes level up to fulminant hepatic failure [20]. Hematological manifestation as leukocytosis with atypical lymphocytes and increased eosinophil are seen in 50% of patients [1]. Other possible abnormalities like carditis, pneumonitis, conjunctivitis, thrombocytopenia, splenomegaly, myalgia and hemolytic anemia can be seen as well [14]. Delayed hypothyroidism for several months after the acute phase has been described in AHS [18]. Rare manifestation like hypersensitivity colitis can be found in this condition, thereby AHS patients may present with diarrhea [21, 22]. Additionally, periorbital or orofacial edema might also be expected [23]. The main organs which are involved in AHS are epidermis in

Table 1  Laboratory findings at both times of admission and discharge

| Initial findings at time of admission | 10 days later at time of discharge |
|--------------------------------------|----------------------------------|
| Hemoglobin 10.4 g/dl                | Hemoglobin 10.9 g/dl             |
| Platelets 105,000/mm³              | Total bilirubin 2.07 mg/dl      |
| White blood cells 10.45 x 10³/µl    | Direct bilirubin 1.68 mg/dl     |
| Neutrophils 4.83 x 10³/µl           | Aspartate aminotransferase 31 IU/l |
| Lymphocytes 3.80 x 10³/µl           | Alanine aminotransferase 96 IU/l |
| Eosinophil 1.60 x 10³/µl            | White blood cells 9.7 x 10³/µl  |
| Alanine aminotransferase 1198 IU/l | Platelets 288,000/mm³           |
| Aspartate Aminotransferase 1338 IU/l | Erythrocytes sedimentation rate 27 mm/h |

| Drug          | Drug reaction                                                                 |
|---------------|-------------------------------------------------------------------------------|
| Phenytoin     | Most common cause of AHS, other reactions include: erythroderma, facial pustules, hyperpigmentation, hypertrichosis and lupus-like symptoms |
| Carbamazepine | Oral ulcers, urticaria, Stevens-Johnson and photosensitivity                   |
| Fosphenytoin  | Bullous rash, erythroderma, pruritus, gingival hyperplasia, lupus-like symptoms and erythema multiforme |
| Lamotrigine   | Hives, swollen glands, painful sores in or around eyes or mouth, difficulty breathing, swelling of face, lips, tongue or throat |

Fig. 5  Atypical lymphocytes on peripheral blood smear

Table 2  Adverse reactions associated with anticonvulsant medications
the skin, clara cell in the lungs, liver and tubular cells in the kidney. All of these cells possess cytochrome P450, which is responsible for metabolism of anti-epileptic medications.

Although reduced immunoglobulins (IgA, IgM, IgG) is noticed at the onset of the hypersensitivity response, several weeks after the suspension of the anti-epileptic medication the immunoglobulins level start to increase [11, 18, 24]. While, several tests used to confirm the diagnosis of AHS, like patch testing and lymphocytes transformation test which is used to assess the drug reactive T cells [18], AHS remains a diagnosis of exclusion which is largely achieved by the following: clinical features, absence of a septic focus and the probable response to steroid treatment [7]. Table 3 summarizes the clinical features of AHS.

The most critical component of management of the AHS is the suspension of all potentially causative anti-epileptic medications [8]. All cases with hypersensitivity must be hospitalized even if the clinical presentation is mild [18]. Mild cases treated with supportive care [18]. The conventional treatment for AHS is systemic glucocorticoids 1–2 mg/kg/day [25] or 40–60 mg/day. The drug of choice is Prednisolone [26], that should be carefully tapered over 6–8 weeks to minimize the chances of relapse [18]. Glucocorticoids, anti-histamines (H1-receptor blockers), epinephrine and airway management all can be used depending on the severity and the extent of the condition [15]. If systemic steroid is not sufficient to alleviate the symptoms, other treatment options are available including plasmapheresis, IVIG [18] and N-acetylcysteine [10]. IVIG has the capability to block the fε receptor of the immunoglobulins by forming different immune complexes and decreasing the inflammatory response. While N-acetylcysteine is solely used in case of hepatic and dermatological compromise, it can buffer the toxic metabolites as well as it has an antiapoptotic effect. In addition to that, N-acetylcysteine has the ability to limit the production and expression of various cytokines and molecules like keratinocyte intercellular adhesion molecule 1 (ICAM-1), that are implicated in the inflammatory cascade of AHS.

The use of antibiotics and NSAIDs carries no benefit in the treatment of AHS, particularly in the acute phase. Moreover, antibiotics and NSAIDs may worsen or even mask the clinical picture of AHS due to the cross-reactivity [18]. In patient requiring ongoing anti-epileptic treatment, sodium valproate considered to be a safe alternative because of its different chemical structure [6]. Careful monitoring of thyroid function test for several months would be valuable in AHS due to the expected late onset hypothyroidism during the course of this reaction.

Although it was postulated that the prognosis of AHS determined by various factors such as; genetic predisposition, patient age, reactivation of some viruses like HHV6, underlying disease process and the type of management [27], we are lacking an accurate clinical tool or scoring system to determine AHS/DRESS prognosis [28].

AHS is a synonymous for drug reaction with eosinophilia and systemic symptoms (DRESS). It is also known as drug induced hypersensitivity syndrome (DIHS), hypersensitivity syndrome (HSS) and drug induced delayed multiorgan hypersensitivity syndrome (DID-MOHS). DRESS is a wider term than AHS that caused by failure of detoxification of several medications [28], including phenytoin, carbamazepine, phenobarbital, zonisamide, mexiletine, lamotrigin, abacavir, nevirapine, dapsone, salazosulfapyridine, allopurinol and minocycline [29]. Although one of the diagnostic criteria of Japanese consensus group to diagnose DRESS is to have reactivation of human herpesvirus 6 (HHV6) [28], the initial HHV6 serological testing for our patient was negative. According to Shiohara et al. DRESS or DIHS pathogenesis is a profound interactions between herpesviruses reactivation (HHV6, HHV7, CMV, EBV), immune response to these viruses and specific immune response to the culprit medication itself [18]. The clinical diagnostic criteria of DRESS based on RegiSCAR group was summarized in Table 4 which fits our patient’s diagnosis with AHS [28, 29].

There are very limited differentials for thousands elevation of liver enzymes as we encountered in our patient. We thought of viral and autoimmune hepatitis at the time of admission. Viral hepatitis was ruled out by negative hepatitis profile. Autoimmune hepatitis (AIH) was kept in mind. AIH was first described in 1950s by Waldenström [30]. The clinical presentation is variable ranging from no obvious signs or symptoms to acute or even fulminant liver disease [31]. AIH affects females more frequently than males with a ratio 3.6:1. Although there is no race predilection in AIH [32], but the age distribution is bimodal, one peak during teenage years and another in fourth and sixth decade of life [31]. AIH is classified into two types. Type one

---

**Table 3 The clinical features of anticonvulsants hypersensitivity syndrome**

| Finding                  | Incidence % |
|-------------------------|-------------|
| Fever                   | 90–100      |
| Skin rash               | 90          |
| Liver involvement       | 50–60       |
| Hematological manifestation | 50         |
Table 4 The clinical criteria for DRESS by RegiSCAR group

- Fever >38 °C
- Enlarged lymph nodes at least of 2 sites
- Involvement of at least one internal organ
- Blood count abnormalities, at least one present. Lymphocytes above or below normal, low platelets and/or eosinophilia
- Hospitalization
- Reaction suspected to be drug related
- Acute rash

At least three of the first four criteria are required to make the diagnosis

A systemic disease like infectious mononucleosis may present with similar manifestations and clinical course as our patient. Infectious mononucleosis is a clinical syndrome caused by EBV and commonly presents in adolescents and children. Based on Hoagland's criteria [33] for EBV infectious mononucleosis, to make the diagnosis, we require at least 50 percent lymphocytes and at least 10 percent atypical lymphocytes in the presence of fever, adenopathy and pharyngitis. The diagnosis confirmed by a positive serologic investigation. Talking about the hematological findings, although the CBC and blood smear of our patient showed lymphocytosis with atypical lymphocytes which are also seen in infectious mononucleosis, it is unlikely to have eosinophilia in infectious mononucleosis as our patient had. However, our patient does not fit the aforementioned criteria for EBV infectious mononucleosis [34]. Despite of the negative serological testing in our patient, reactivation of EBV, CMV, HHV 6 and HHV 7 were also detected in DRESS by running longitudinal studies using PCR to test viral DNA [28].

Adult onset still’s disease (AOSD) can mimic the clinical findings of AHS. AOSD is a rare systemic inflammatory disease. It has been described all over the world and has a bimodal age distribution; the first peak occurs at 15–25 years of age and the second one usually occurs within 36–46 years. It is characterized by the classical triad of persistent high spiking fever, arthralgia and salmon colored skin rash. AOSD is typically a diagnosis of exclusion and should be considered after excluding infectious, malignant and other connective tissue diseases. Our patient does not fit the typical presentation of AOSD [35].

It is uncommon for Kawasaki disease to present in our patient age. However, it would be more significant to think of Kawasaki if the patient presented earlier. It is a clinical diagnosis which occurs mainly below age of 5 years [36]. Clinical Criteria for Kawasaki disease diagnosis are summarized in Table 5. Transthoracic Echocardiography was done in our patient to rule out coronary aneurysm, which did not show any significant finding.

Conclusions

AHS is a diagnosis of exclusion and it is significantly underreported which requires a high index of suspicion. We liked to share this case and shed the light in more details on AHS/DRESS. Our goal was to help making AHS more reported in the literature by adolescents patients, as well as to make physicians more alert of this condition’s seriousness when they prescribe antiepileptic medications in particular. In this report, we included the first case of AHS which was reported in an adolescent patient in Palestine. Moreover, we reviewed the available literature for a better understanding of the pathophysiology and management of AHS. We still believe that the full understanding of the pathogenesis of AHS is lacking, and also we are lacking a clinical tool or scoring system to determine the severity of AHS/DRESS.

Table 5 Clinical features for diagnosing Kawasaki disease

| Classical Kawasaki | Classical Kawasaki with alternative diagnostic criteria | Atypical Kawasaki |
|--------------------|--------------------------------------------------------|--------------------|
| Constant fever of at least 5 days and at least 4 of the principle features | Constant fever of at least 5 days, two or three of principle features, coronary abnormalities on transthoracic echocardiography | Constant fever of at least 5 days, two or three of the principle features |
| Principle features of Kawasaki disease diagnosis | | |
| Changes in the oral cavity and lips like strawberry tongue, erythematous lips (96.5%) | | |
| Polymorphous rash (96%) | | |
| Bilateral non-purulent conjunctivitis (89%) | | |
| Changes in the extremities like erythema, desquamation in hands and feet in week 2 and 3 (75.6%) | | |
| Cervical lymphadenopathy more than 1.5 cm in diameter, mainly unilateral (62.7%) | | |
Abbreviations
AHS: anticonvulsant hypersensitivity syndrome; ADR: adverse drug reaction; AEDS: antiepileptic drugs; LP: lumbar puncture; EBV: Epstein Barr virus; CMV: cytomegalovirus; HSV: Herpes simplex virus; DRESS: drug reaction with eosinophilia and systemic syndrome; HLA: human leukocyte antigen; IL: interleukin; IVIG: intravenous immunoglobulin; ICAM-1: keratinocyte intercellular adhesion molecule 1; NSAIDs: non steroidal anti-inflammatory drugs; ANAs: antinuclear antibodies; ASMA: anti smooth muscle antibodies; Anti-LKM1: anti liver-kidney microsomal type 1 antibody; Anti-LC1: anti liver cytosol type 1 antibody; AOSD: adult onset still’s disease; NNUH: An-Najah National University Hospital, AlN: autoimmune hepatitis; DRESS: drug reaction with eosinophilia and systemic symptoms; DIHS: drug induced hypersensitivity syndrome; HSS: hypersensitivity syndrome; DISMOHS: drug induced delayed multiorgan hypersensitivity syndrome; HHV6: human herpesvirus 6; HHV7: human herpesvirus 7.

Authors’ contributions
MG and QA were responsible for the clinical management of the patient. SM and AN participated in the design and revision of the case report and collected the data. All authors read and approved the final manuscript.

Author details
1 AN-Najah National University Teaching Hospital, Asira, Nablus, West bank, Palestine. 2 AN-Najah National University, Nablus, West bank, Palestine.

Acknowledgements
The authors thank the patient and her parents who generously agreed to participate in this medical report.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All the data supporting our findings is contained within manuscript.

Consent for publication
Written informed consent was obtained from the patient’s legal guardian(s) for publication of this case report and any accompanying images.

Ethics approval and consent to participate
There was no ethics committee approval as the data has been analyzed in a retrospective manner and has no effect on treatment of the patient.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 March 2017   Accepted: 12 June 2017
Published online: 15 June 2017

References
1. Shivamurthy S, Manchukonda R. Carbamazepine induced anticonvulsant hypersensitivity syndrome. Int J Basic Clin Pharmacol. 2015;4(5):1037–9.
2. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia. 1998;39:53–7.
3. Descamps V, Ranger-Rogez S. DRESS syndrome. Joint Bone Spine. 2014;81(1):15–21.
4. Brown SC, Dauterive RL. Anticonvulsant hypersensitivity syndrome secondary to carbamazepine. In Baylor University Medical Center Proceedings; 2017.
5. Meritt HH, Putnam TJ. Landmark article Sept 17, 1938: sodium diphenyl hydantoin in the treatment of convulsive disorders. JAMA. 1984;251(18):1062–7.
6. Gupta D, Forbes M, McKean M. Anticonvulsant hypersensitivity syndrome. J Pharm Pract Res. 2016;46(2):143–4.
7. Pillai L, et al. Hypersensitivity and dose related side effects of phenyoitin mimicking critical illness. Indian J Crit Care Med. 2005;9(1):22–7.
8. Schweitzer I. Anticonvulsant hypersensitivity syndrome: a rare and serious complication. Med J Aust. 2011;194(11):609–10.
9. Blaszyk B, et al. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. Pharmacol Rep. 2013;65(2):399–409.
10. Cumbo-Nacheli G, et al. Anticonvulsant hypersensitivity syndrome: is there a role for immunomodulation? Epilepsia. 2008;49(12):2108–12.
11. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol. 2004;140(2):183–8.
12. Okada K, et al. Phenytoin promotes Th2 type immune response in mice. Clin Exp Immunol. 2001;124(3):406–13.
13. Singer MI, Shapiro LE, Shear NH. Cytochrome CYP450A: interactions with dermatologic therapies. J Am Acad Dermatol. 1997;37(5 Pt 1):765–71.
14. Meik S, et al. Anticonvulsant hypersensitivity syndrome (DRESS syndrome): report of 4 cases. Dermatol Argent. 2010;2013(16):272–7.
15. Mehta M, et al. Anticonvulsant hypersensitivity syndrome associated with carbamazepine administration: case series. J Pharmaco Pharmaco. 2014;5(1):59.
16. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest. 1988;82(6):1826–32.
17. Geduk A, et al. Late-onset anticonvulsant hypersensitivity syndrome mimicking lymphoma. Intern Med. 2015;54(24):3201–4.
18. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antiderm immune responses. Allergol Int. 2006;55(1):1–8.
19. Ang CC, et al. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol. 2010;63(2):219–27.
20. Kennebeck GA. Anticonvulsant hypersensitivity syndrome. J Am Board Fam Pract. 2000;13(3):364–70.
21. Anttila VJ, Valtonen M. Carbamazepine-induced eosinophilic colitis. Epilepsia. 1992;33(1):119–21.
22. Eland IA, et al. Colitis may be part of the antiepileptic drug hypersensitivity syndrome. Epilepsia. 1999;40(12):1780–3.
23. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995;155(21):2265–90.
24. Mlodzowska-Albrecht J, Steinborn B, Zaworski M. Cytokines, epilepsy and epileptic drugs—is there a mutual influence? Pharmaco Rep. 2007;59(2):129–38.
25. Suzuki Y, et al. Carbamazepine-induced drug-induced hypersensitivity syndrome in a 14-year-old Japanese boy. Epilepsia. 2008;49(12):2118–21.
26. Eguchi E, et al. Granulomatous interstitial nephritis associated with atypical drug-induced hypersensitivity syndrome induced by carbamazepine. Clin Exp Nephrol. 2012;16(1):168–72.
27. Ono Y, et al. Drug-induced hypersensitivity syndrome caused by carbamazepine used for the treatment of trigeminal neuralgia. Case Rep Dermatol. 2016;2016;460623.
28. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):16–11.
29. Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf. 2017;16(2):139–47.
30. Liberal R, Vergani D, Mieli-Vergani G. Update on autoimmune hepatitis. J Clin Transl Hepatol. 2015;3(1):142–52.
31. EASL Clinical Practice Guidelines. Autoimmune hepatitis. J Hepatol. 2010;53(4):971–1004.
32. Manns MP, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):219–21.
33. Hoagland RJ. Infectious mononucleosis. Prim Care. 1975;2(2):295–307.
34. Ebell MH. Epstein–Barr virus infectious mononucleosis. Am Fam Phys. 2004;70(7):1279–87.
35. Gopalarathanam R, et al. Adult onset still’s disease: a review on diagnostic workup and treatment options. Case Rep Rheumatol. 2016;2016;6502373.
36. Saguil A, Fargo M, Grogan S. Diagnosis and management of Kawasaki disease. Am Fam Phys. 2015;91(6):365–71.